ATE348827T1 - Substituierte benzofurane und benzothiophene, verfahren zu deren herstellung und verfahren zu deren anwendung als integrinantagonisten - Google Patents

Substituierte benzofurane und benzothiophene, verfahren zu deren herstellung und verfahren zu deren anwendung als integrinantagonisten

Info

Publication number
ATE348827T1
ATE348827T1 AT02766847T AT02766847T ATE348827T1 AT E348827 T1 ATE348827 T1 AT E348827T1 AT 02766847 T AT02766847 T AT 02766847T AT 02766847 T AT02766847 T AT 02766847T AT E348827 T1 ATE348827 T1 AT E348827T1
Authority
AT
Austria
Prior art keywords
sup
sub
alpha
beta
benzothiophenes
Prior art date
Application number
AT02766847T
Other languages
English (en)
Inventor
Juan Jose Marugan Sanchez
Victor J Marder
Prichard David C U
Beth M Anaclerio
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of ATE348827T1 publication Critical patent/ATE348827T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Furan Compounds (AREA)
AT02766847T 2001-04-27 2002-04-29 Substituierte benzofurane und benzothiophene, verfahren zu deren herstellung und verfahren zu deren anwendung als integrinantagonisten ATE348827T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28653201P 2001-04-27 2001-04-27
US32451601P 2001-09-26 2001-09-26

Publications (1)

Publication Number Publication Date
ATE348827T1 true ATE348827T1 (de) 2007-01-15

Family

ID=26963889

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02766847T ATE348827T1 (de) 2001-04-27 2002-04-29 Substituierte benzofurane und benzothiophene, verfahren zu deren herstellung und verfahren zu deren anwendung als integrinantagonisten

Country Status (11)

Country Link
US (3) US6872730B2 (de)
EP (1) EP1390362B1 (de)
JP (1) JP2004527559A (de)
KR (1) KR20040007507A (de)
AT (1) ATE348827T1 (de)
CA (1) CA2445629A1 (de)
DE (1) DE60216910T2 (de)
ES (1) ES2276955T3 (de)
MX (1) MXPA03009716A (de)
NZ (1) NZ528853A (de)
WO (1) WO2002088118A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05006587A (es) 2002-12-20 2005-12-14 Pharmacia Corp Compuestos de tiazol como derivados de antagonistas del receptor de la integrina.
EP3050878B1 (de) 2013-09-24 2021-10-27 FUJIFILM Corporation Neuartige stickstoffhaltige verbindung oder salz davon oder metallkomplex davon
EA201991123A1 (ru) * 2016-11-08 2019-11-29 ИНДАЗОЛОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АНТАГОНИСТОВ ИНТЕГРИНА αV

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4027278A1 (de) 1990-08-29 1992-03-05 Bayer Ag Heterocyclisch substituierte indolsulfonamide
JPH0764841B2 (ja) 1990-10-03 1995-07-12 ファイザー製薬株式会社 インドール誘導体およびその用途
GB9309324D0 (en) 1993-05-06 1993-06-16 Bayer Ag Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives
GB9317764D0 (en) 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
CA2190870A1 (en) 1994-05-27 1995-12-07 George D. Hartman Compounds for inhibiting osteoclast-mediated bone resorption
MX9801228A (es) 1995-08-14 1998-05-31 Scripps Research Inst METODOS Y COMPOSICIONES UTILES PARA LA INHIBICION DE ANGIOGENESIS MEDIADA POR ALFAV beta5.
DE19548709A1 (de) 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
PT891325E (pt) 1996-03-29 2002-07-31 Searle & Co Derivados do acido fenilpropanoico para-substituido como antagonistas de integrina
KR20000016301A (ko) 1996-05-31 2000-03-25 빙검 더글라스 에이. 혈관 형성 억제에 유용한 방법 및 조성물
CA2259224A1 (en) 1996-06-28 1998-01-08 Merck Patent Gesellschaft Mit Beschraenkter Haftung Phenylalamine derivatives as integrin inhibitors
EP0949259B1 (de) 1996-12-26 2001-06-20 Nikken Chemicals Company, Limited N-hydroxyharnstoffderivate und sie enthaltende medizinische zubereitungen
US6066648A (en) 1997-12-17 2000-05-23 Merck & Co., Inc. Integrin receptor antagonists
ATE299023T1 (de) 1997-12-17 2005-07-15 Merck & Co Inc Integrinrezeptor antagonisten
GB9814801D0 (en) 1998-07-09 1998-09-09 Univ Strathclyde Integrin dependent cell adhesion inhibitors
UA71586C2 (en) 1998-12-04 2004-12-15 Smithkline Beecham Corp A vitronectin receptor antagonist
CN1398189A (zh) 1998-12-23 2003-02-19 G.D.西尔公司 用于治疗肿瘤形成的放疗与cox－2抑制剂的联合治疗
DE10006139A1 (de) 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate

Also Published As

Publication number Publication date
US20050228011A1 (en) 2005-10-13
EP1390362A1 (de) 2004-02-25
JP2004527559A (ja) 2004-09-09
US6872730B2 (en) 2005-03-29
DE60216910T2 (de) 2007-10-18
EP1390362B1 (de) 2006-12-20
DE60216910D1 (de) 2007-02-01
US20030018064A1 (en) 2003-01-23
US20050165036A1 (en) 2005-07-28
MXPA03009716A (es) 2004-03-10
ES2276955T3 (es) 2007-07-01
NZ528853A (en) 2006-03-31
WO2002088118A1 (en) 2002-11-07
CA2445629A1 (en) 2002-11-07
KR20040007507A (ko) 2004-01-24

Similar Documents

Publication Publication Date Title
ATE530183T1 (de) Substituierte indole und ihre verwendung als integrin-antagonisten
NO20050068L (no) Nye karboksamid-forbindelser med en mch-antagonist-virkning, medikamenter inneholdende disse forbindelsene, og fremgangsmater for fremstilling derav
DE60038686D1 (de) Oheptan-derivate und ihre verwendung als integrin-rezeptor-antagonisten
DZ3263A1 (fr) Antagonistes du recepteur de l'alpha v integrine
BRPI0408681A (pt) compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos
ATE236626T1 (de) Integrin antagonist
DK1274692T3 (da) Quinazolinforbindelser
EP0901373A4 (de) Alpha v Beta 3 ANTAGONISTEN
EA200400466A1 (ru) Производные пиперазина с антагонистической активностью к рецептору ccr1
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
ATE299023T1 (de) Integrinrezeptor antagonisten
DE602004017777D1 (de) Tricyclische indolhydroxyethylaminderivate und deren verwendung bei der behandlung von alzheimer-krankheit
ES2159717T3 (es) Derivados de acido 5-(piperidinil-1 sustituido en posicion 4)-3-aril-pentanoico como antagonistas de los receptores de taquiquinina.
DE602004011204D1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
EP1315501A4 (de) Alpha v integrin-rezeptor-antagonisten
EA200501148A1 (ru) Пиридилоксиметильные и бензизоксазольные азабициклические производные
DE60216910D1 (de) Substituierte benzofurane und benzothiophene, verfahren zu deren herstellung und verfahren zu deren anwendung als integrinantagonisten
DE60042446D1 (de) Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen
DK1534352T3 (da) Implantat til transport og afgivelse af farmakologisk aktive midler såvel som en fremgangsmåde til fremstilling af samme
DE602004021399D1 (de) Aminobenzimidazole als selektive melanin-konzentrierende hormon-rezeptorantagonisten zur behandlung von fettsucht und verwandten erkrankungen
DE60224509D1 (de) Imidazolderivate verwendbar als histamin h3 rezeptorliganden
ATE365155T1 (de) 1,3-disubstituierte azetidinderivate zur verwendung als antagonisten des ccr-3-rezeptors bei der behandlung von entzündlichen und allergischen krankheiten
ATE469146T1 (de) Benzofuranderivate und deren verwendung bei der behandlung von mikrobiellen infektionen
DE60321354D1 (de) Selektive d1/d5 rezeptorantagonisten zur behandlung von fettleibigkeit und von zns störungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties